ymabs.com Open in urlscan Pro
2606:4700:3031::6815:1ab3  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Our Company
   * Overview
   * Corporate Governance
     * Leadership
     * Board of
       Directors
   * Working
     at Y-mAbs
   * Careers
   * Contact Us
   * Safety
   * Culture of Integrity
   * Community Guidelines
 * Our Focus
   * Overview
   * Neuroblastoma
   * CNS/LM
   * Osteosarcoma
   * DIPG
   * Medulloblastoma
   * DSRCT
 * Our Research & Development
   * Overview
   * Platforms
     * Immunotherapy
     * Radioimmunotherapy
     * Companion Diagnostics
   * Our Pipeline
   * Partnering & Collaboration
 * Our Products
   * DANYELZA®
 * Our Patient & Family Support
   * Overview
   * Access to
     Clinical Trials
   * Expanded Access Programs & Policies
 * For Medical Professionals
   * Overview
   * Clinical Trials
   * Medical Website
 * For Investors
   * Overview
   * Stock Information
     * Stock Quote & Chart
   * News & Presentations
     * Press Releases
     * Events
     * Presentations
   * Financial Information
     * SEC Filings
     * Annual Reports
   * Corporate Governance
     * Governance Overview
     * Leadership
     * Board of Directors
     * Committee Composition
   * Investor Resources
     * Investor FAQs
     * Email Alerts
     * Contact IR

Innovative pediatric immunotherapies for


REAL-LIFE POSSIBILITIES


ABOUT Y-MABS THERAPEUTICS

Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the
development and commercialization of novel, antibody-based therapeutic products
for the treatment of cancer. We have a broad and advanced product pipeline,
including pivotal-stage product candidates against a range of targets.

Our mission is to become the world leader in developing better and safer
antibody-based oncology products addressing clear unmet pediatric and adult
medical needs. With the right partnerships and collaborations, we envision
changing the course of cancer care and its outcomes.

Learn more
View Y-mAbs Therapeutics, Inc SADA presentation


WHAT'S NEW

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on
November 7, 2022

Learn more

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

Learn more

Y-mAbs Announces Pivotal Data for Omburtamab

Learn more
Read more


OUR FOCUS

Neuroblastoma: A rare pediatric cancer of the nervous system that usually starts
on the glands above the kidney and can spread to the abdomen, spine, chest,
neck, or pelvis.

Central Nervous System (CNS)/Leptomeningeal Metastases (LM): This condition
occurs when cancer spreads to the membranes lining the brain and spinal cord.
This can result from many types of cancer, including neuroblastoma.

Osteosarcoma: A cancer that starts in the bones and often develops around the
knee or the upper arm.

Diffuse Intrinsic Pontine Glioma (DIPG): A highly aggressive and
difficult-to-treat tumor found at the base of the brain.

Medulloblastoma: A type of cancer that starts in the lowest back part of the
brain (the cerebellum). Although rare, it is the most common cancerous brain
tumor found in children.

Desmoplastic Small Round Cell Tumor (DSRCT): A rare tumor that is usually
located in the abdomen.

Learn more


OUR RESEARCH
& DEVELOPMENT


WHAT IS ANTIBODY IMMUNOTHERAPY AND HOW CAN IT HELP?

Antibody immunotherapy is a type of treatment that’s designed to target specific
antigens (molecules that stimulate an immune response) in the body and
neutralize them. In early and ongoing clinical trials, the antibodies developed
by Y-mAbs have shown results that garner continued evaluation.

Learn more



OUR PATIENT
& FAMILY SUPPORT

Y-mAbs was founded by Thomas Gad, President and Head of Business Development and
Strategy, who is also the father of a high-risk neuroblastoma survivor.

After years of searching for an effective option for neuroblastoma, Gad's
daughter received treatment from Memorial Sloan Kettering Cancer Center (MSKCC).
Since then, Gad has envisioned helping other patients and families get access to
the same products.

Y-mAbs may someday help patients fight cancer with their advanced pipeline of
antibody immunotherapies, which are currently being investigated in ongoing
clinical trials.

Learn more


FOR MEDICAL
PROFESSIONALS

Pediatric cancer has long been a challenge for the medical profession.  With
years of growing knowledge and insights, treatment advancements are being made
through research.

Y-mAbs is working to develop targeted approaches to treating rare and
challenging pediatric cancers with the hope of extending survival and helping
with safety concerns.

Learn more


FOR
INVESTORS

Y-mAbs Therapeutics, Inc. (Y-mAbs), is a state-of-the-art, late-stage clinical,
global biopharmaceutical company that is focused on the research and development
of innovative antibody-based products under investigation using a range of
cutting-edge technologies, licensed from one of the largest and most prestigious
cancer-care establishments in the world—MSKCC.

With its robust pipeline, Y-mAbs is committed to becoming a world leader in
creating pediatric-based oncology treatments.

Learn more
Privacy Statement
Terms of Use
Contact Us
References

© 2022 Y-mAbs Therapeutics, Inc. All rights reserved.
NP-000040

YOU ARE LEAVING THIS WEBSITE

×

You are about to leave ymabs.com. The link will take you to a website that may
be maintained by a third party, which is solely responsible for its content.
Y-mAbs Therapeutics, Inc provides this link as a service to its web visitors,
and is not responsible for the privacy policy or terms of use of any third-party
website.

Close Continue
Close ×
Please click for full Prescribing Information and Patient Information for
DANYELZA including BOXED WARNING on serious infusion-related reactions and
neurotoxicity.
Learn more at danyelza.com


INDICATION

DANYELZA is indicated, in combination with granulocyte-macrophage
colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1
year of age and older and adult patients with relapsed or refractory high-risk
neuroblastoma in the bone or bone marrow who have demonstrated a partiaI
response, minor response, or stable disease to prior therapy.

This indication is approved under accelerated approval based on overalI response
rate and duration of response. Continued approval for this indication may be
contingent upon verification and description of clinical benefit in a
confirmatory trial(s).


SELECTED IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFUSION-RELATED REACTIONS and NEUROTOXICITY

Serious Infusion-Related Reactions

 * DANYELZA can cause serious infusion reactions, including cardiac arrest,
   anaphylaxis, hypotension, bronchospasm, and stridor. Infusion reactions of
   any Grade occurred in 94-100% of patients. Severe infusion reactions occurred
   in 32-68% and serious infusion reactions occurred in 4-18% of patients in
   DANYELZA clinical studies.
 * Premedicate prior to each DANYELZA infusion as recommended and monitor
   patients for at least 2 hours following completion of each infusion. Reduce
   the rate, interrupt infusion, or permanently discontinue DANYELZA based on
   severity.

Neurotoxicity

 * DANYELZA can cause severe neurotoxicity, including severe neuropathic
   pain,transverse myelitis and reversible posterior leukoencephalopathy
   syndrome (RPLS). Pain of any Grade occurred in 94-100% of patients in
   DANYELZA clinical studies.
 * Premedicate to treat neuropathic pain as recommended. Permanently discontinue
   DANYELZA based on the adverse reaction and severity.